Video duration 24 minutes 30 seconds
Japanese and US pharmaceuticals announced the results of a trial hailed as a breakthrough.
Data from Japanese and US pharmaceutical companies show that a new drug can significantly slow cognitive decline in Alzheimer’s patients by up to 27%.
The 18-month trial involved nearly 2,000 people in the early stages of the disease.
Dementia costs more than a trillion dollars globally, and early detection is crucial to recognizing the signs of Alzheimer’s disease or other cognitive impairments.
So what will be the effect of this new drug?
Indicator: Mohammed Jamjoom
Guest:
Graeme Sutherland – Son of someone with Alzheimer’s and social media ambassador for Alzheimer’s Scotland
Bart De Strooper – Director of Dementia Research UK
Susan Kohlhaas – Research Director at Alzheimer’s Research UK
